Pharvaris (NASDAQ:PHVS) Shares Gap Down – Should You Sell?

Pharvaris (NASDAQ:PHVS)’s share price gapped down prior to trading on Monday . The stock had previously closed at $16.67, but opened at $16.23. Pharvaris shares last traded at $16.77, with a volume of 4,984 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, JMP Securities upped their price target on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Stock Down 2.8 %

The firm has a market cap of $847.41 million, a price-to-earnings ratio of -6.03 and a beta of -3.02. The business has a 50 day moving average price of $17.13 and a 200-day moving average price of $19.13.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Pharvaris by 30.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company’s stock valued at $1,222,000 after purchasing an additional 14,838 shares during the last quarter. Woodline Partners LP purchased a new position in Pharvaris in the fourth quarter valued at about $853,000. Soleus Capital Management L.P. boosted its holdings in Pharvaris by 36.2% in the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock valued at $15,617,000 after purchasing an additional 216,483 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Pharvaris in the fourth quarter valued at about $152,000. Finally, Octagon Capital Advisors LP boosted its holdings in Pharvaris by 25.4% in the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock valued at $14,914,000 after purchasing an additional 157,530 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.